# Institutional Clinical and Translational Science Award

> **NIH NIH UL1** · UNIVERSITY OF PENNSYLVANIA · 2024 · $10,230,682

## Abstract

OVERALL
ABSTRACT/SUMMARY
The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in
Penn. For the past decade and a half the objectives of ITMAT have been and remain (i) to
increase the number of investigators capable of pursuing their research between proof of
concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology,
disease or drug action through intense phenotyping in small numbers of people. The two
priorities of our CTSA are to foster the field of translational therapeutics and to bridge the
pediatric to adult divide across the entire spectrum of clinical and translational science. This
section describes how these priorities have influenced the growth of this CTSA Hub and outlines
our plans for the coming funding period.

## Key facts

- **NIH application ID:** 10878821
- **Project number:** 5UL1TR001878-09
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** GARRET A FITZGERALD
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $10,230,682
- **Award type:** 5
- **Project period:** 2016-07-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10878821

## Citation

> US National Institutes of Health, RePORTER application 10878821, Institutional Clinical and Translational Science Award (5UL1TR001878-09). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10878821. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*